Viagra, Cheap Viagra, Online Pharmacy - We have compared more than 30 online pharmacies and help you find the cheapest Viagra online

Like a Teenager

I have had problems recently getting a full erection and it has started affecting my relationship with my girl. I got a sample pack of Viagra, and let me say that this stuff is the bomb. I took one before we watched a movie the other night, and then we had sex about three hours later. I haven't been that hard since I was a teenager. She was so turned on by my erection. She immediately began sucking and licking my penis. I could tell she loved it. Then she rode me hard and came many times. Then I rolled her over doggy style and gave her a few more orgasms before burying my load in her

Confidence is Back

I recently entered a new relationship after having ended a long term one shortly before. I found, much to my annoyance and frustration, that when it came to being intimate with my new partner, I was having problems maintaining a full erection or one at all. I am sure it was purely a psychological problem as it had never been an issue in my previous relationship. 

After the first time it happened, I found myself getting more and more worked up about it, and putting more and more pressure on myself, my confidence was totally shot. I did try herbal alternatives (which I found out about on the net), and although they made a slight difference to my general energy levels, didn't perform when it came to improving my erections. Viagra worked excellently the very first time I took half a 50mg pill. My confidence is back, and I am now having great sex without having to take it at all. It was definitely worth the price..

Peroxynitrite-induced relaxation in isolated rat aortic rings and mechanisms of action.

Li J, Li W, Altura BT, Altura BM.

Department of Physiology and Pharmacology, State University of New York, Health Science Center at Brooklyn, Brooklyn, NY 11203, USA; The Central Lab of Shandong Provincial Hospital, Jinan, P.R. China.

The present study was designed to evaluate the effects of peroxynitrite (ONOO(-)), the product of superoxide and nitric oxide, on isolated segments of rat aorta. In the absence of any vasoactive agent, ONOO(-) (from 10(-8) to 10(-4) M) failed to alter the basal tension. In phenylephrine (PE; 5 x 10(-7) M)-precontracted rat aortic rings (RAR), ONOO(-) elicited concentration-dependent relaxation at concentrations of from 10(-8) to 10(-4) M. The effective concentrations producing approximately 50% of maximal relaxation (ED(50)) to ONOO(-) were 1.84 x 10(-5) M and 1.96 x 10(-5) M in intact and denuded RAR, respectively (P > 0.05). No significant differences in the relaxation responses were found between RAR with or without endothelium (P > 0.05). The presence of either 5 muM methylene blue (MB) or 5 muM 1H-[1,2,4]oxadiazolo-[4,3-alpha]quinoxalin-1-one (ODQ) significantly inhibited the relaxations induced by ONOO(-). Sildenafil (10(-7) M), on the other hand, significantly potentiated the ONOO(-)-induced relaxations. Tetraethylammonium chloride (T-2265) significantly decreased the ONOO(-)-induced relaxations in a concentration-dependent manner. However, ONOO(-) had no effect on RAR precontracted by high KCL (40 mM, n = 6, P > 0.05). Addition of calyculin A also significantly decreased the ONOO(-)-induced relaxation in a dose-dependent manner. Furthermore, ONOO(-) significantly inhibited calcium-induced contractions of K(+)-depolarized aortic rings in a concentration-related manner. Lastly, a variety of other pharmacological agents and antagonists including l-NMMA, l-arginine, indomethacin, atropine, naloxone, diphenhydramine, cimetine, glibenclamide, haloperidol, superoxide dismutase (SOD), and catalase did not influence the relaxant effects of ONOO(-) on RAR. Our new results suggest that ONOO(-)-triggered relaxation on rat aortic rings is mediated by elevation of cGMP levels, membrane hyperpolarization via K(+)-channel activation, activation of myosin phosphatase activity, and interference with calcium movement and cellular membrane Ca(2+) entry.

Past, present, and future: a 7-year update of Viagra (sildenafil citrate).

Jackson G, Gillies H, Osterloh I.

Guys and St.Thomas Hospital Trust, London, UK.

Summary More than 30 million men are estimated to have erectile dysfunction (ED) in the United States (Feldman et al. J Urol 1994;151: 54-61). Worldwide, ED is estimated to affect more than 150 million men, and that number is expected to exceed 300 million men by the year 2025 (Aytac et al. BJU Int 1999;84: 50-6). The prevalence of ED ranges from 7% in men aged 18-29 years (Laumann et al. JAMA 1999;281: 537-44) to 85% in men aged 76-85 years. In addition, a recent report showed that 68% of patients with ED aged 18 years and older have at least one comorbid diagnosis of hypertension, hyperlipidaemia, diabetes or depression (Seftel et al. J Urol 2004;171: 2341-5), and research suggests that ED may be an early indicator of systemic vascular disease (Kaiser et al. J Am Coll Cardiol 2004;43: 179-84). Viagra((R)) (sildenafil citrate), the first-in-class phosphodiesterase type 5 (PDE5) inhibitor, was introduced in 1998 for the treatment of ED (Boolell et al. Br J Urol 1996;78: 257-61; Boolell et al. Int J Impot Res 1996;8: 47-52). In the 7 years since its market launch, more than 750,000 physicians have prescribed sildenafil to more than 23 million men, helping establish an excellent safety and efficacy record. Clinical studies have demonstrated that sildenafil successfully treats ED of varied organic, psychogenic or mixed aetiology, and is effective in men with ED and comorbidities such as hypertension, hyperlipidaemia, diabetes or depression. Sildenafil was a breakthrough medication that addressed a previously unfulfilled medical need. The impact of sildenafil has stimulated academic, clinical and industrial research to better understand the nature of sexual function and develop better treatment and management for sexual dysfunctions such as ED. With the advent of other erectogenic therapies for the treatment of ED, this 7-year update will focus on the unique history and development of sildenafil, its current use and applications and its future directions and indications. Special emphasis is placed on the impact of sildenafil on our understanding of sexual health and on the extensive safety and efficacy data that have been amassed from numerous clinical trials.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15924597&query_hl=1